Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1957 Aug 1;106(2):273–292. doi: 10.1084/jem.106.2.273

THE PATHOGENESIS OF HEMOPHILIA

AN EXPERIMENTAL ANALYSIS OF THE ANTICEPHALIN HYPOTHESIS IN HEMOPHILIC DOGS

John B Graham 1, Emily M Barrow 1
PMCID: PMC2136750  PMID: 13449237

Abstract

It has been possible to duplicate in the hemophilic dog four of the major experiments which have suggested in humans an "anticephalin" hypothesis for the pathogenesis of hemophilia. The experiments in the dog have been considerably extended, as compared with the human experiments, by a variety of techniques. I. Asbestos was placed in contact with hemophilic dog plasma, and the clotting time became shorter. When transfused, this plasma had no effect on the defective prothrombin utilization of hemophilic dogs, in contrast to untreated normal plasma. II. The ionic strength of native dog plasma and dog plasma citrated (38 per cent sodium citrate) then recalcified (0.2 M CaCl2) were calculated. The ionic strength of the native plasma was approximately 0.15 while that of the citrated plasma was approximately 0.21. Conductivity and freezing point determinations on the plasmas described above were consistent with the idea that the ionic strength of the citrated plasma was significantly higher. The biphasic dilution curve, to which much significance has been attached in arriving at the "anticephalin" hypothesis, can be produced readily in the dog. Diluting dog plasma with "iso-ionic" or "hyper-ionic" NaCl solution abolished the biphasic phenomenon. Dilution with distilled water exaggerated the biphasic curve. These experiments suggest that the biphasic curve is an artifact of uncontrolled ionic strength. III. The prothrombin utilization rates of undiluted whole hemophilic dog blood and hemophilic dog blood diluted 1:2 with 0.85 per cent NaCl were found to be the same. IV. Ether extraction of both normal and hemophilic dog plasma removed fibrinogen and reduced somewhat the concentration of prothrombin. In treated normal plasma AHF was reduced to the level of untreated hemophilic plasma, thus producing a quasi-hemophilic plasma. Defibrination and ether extraction of both normal and hemophilic dog plasma "generated" clotting activity which shortened the clotting time of hemophilic plasma and was active in the thromboplastin generation test. The activity "generated" by defibrination and ether extraction of dog plasma was adsorbed by a BaSO4 suspension and shown, therefore, not to be the anti-hemophilic factor (AHF). Transfusion of ether-extracted normal or hemophilic dog plasma into hemophilic dogs had no effect on the prothrombin utilization rate, unlike untreated normal plasma which had a marked effect. Thus, four of the main lines of evidence supporting the "anticephalin" hypothesis were duplicated in the dog. However, by extending the experiments it was found that all were explainable on bases other than the presence of "anticephalin." Such an hypothesis is not necessary, therefore, to explain the pathogenesis of canine hemophilia. The apparent identity of hemophilia in the two species suggests that the hypothesis is also not applicable to humans.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BIGGS R., DOUGLAS A. S. The thromboplastin generation test. J Clin Pathol. 1953 Feb;6(1):23–29. doi: 10.1136/jcp.6.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BRINKHOUS K. M., GRAHAM J. B. Hemophilia and the hemophilioid states. Blood. 1954 Mar;9(3):254–257. [PubMed] [Google Scholar]
  3. BRINKHOUS K. M., PENICK G. D., LANGDELL R. D., WAGNER R. H., GRAHAM J. B. Physiologic basis of transfusion therapy in hemophilia. AMA Arch Pathol. 1956 Jan;61(1):6–10. [PubMed] [Google Scholar]
  4. BRINKHOUS K. M., PENICK G. D. Relative stability of plasma antihemophilic factor (AHF) under different conditions of storage. Am J Med Sci. 1956 Oct;232(4):434–442. doi: 10.1097/00000441-195610000-00010. [DOI] [PubMed] [Google Scholar]
  5. GRAHAM J. B., BUCKWALTER J. A. Canine hemophilia; observations on the course, the clotting anomaly, and the effect of blood transfusions. J Exp Med. 1949 Aug 1;90(2):97–111. doi: 10.1084/jem.90.2.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. GRAHAM J. B., COLLINS D. L., Jr, GODWIN I. D., BRINKHOUS K. M. Assay of plasma antihemophilic activity in normal heterozygous (hemophilia) and prothrombinopenic dogs. Proc Soc Exp Biol Med. 1951 Jun;77(2):294–296. doi: 10.3181/00379727-77-18755. [DOI] [PubMed] [Google Scholar]
  7. GRAHAM J. B., LANGDELL R. D., MORRISON F. C., Jr, BRINKHOUS K. M. Serum accelerator factors and antihemophilic factor (AHF) in early phases of clotting. Proc Soc Exp Biol Med. 1954 Oct;87(1):45–48. doi: 10.3181/00379727-87-21280. [DOI] [PubMed] [Google Scholar]
  8. GRAHAM J. B., PENICK G. D., BRINKHOUS K. M. Utilization of the antihemophilic factor during clotting of canine blood and plasma. Am J Physiol. 1951 Mar;164(3):710–715. doi: 10.1152/ajplegacy.1951.164.3.710. [DOI] [PubMed] [Google Scholar]
  9. GUILLOT M., FIEHRER A., GUIET R. L'effet de la dilution sur la coagulation du plasma "in vitro" (coagulation normale; coagulation retardée et coagulation hémophilique). Sang. 1950;21(8):732–740. [PubMed] [Google Scholar]
  10. JOHNSON S. A. Activation of purified prothrombin with hemophilic plasma. Am J Clin Pathol. 1953 Sep;23(9):875–880. doi: 10.1093/ajcp/23.9.875. [DOI] [PubMed] [Google Scholar]
  11. JOHNSON S. A., DEUTSCH E., SEEGERS W. H. Ultracentrifugal separation of coagulation factors: platelet cofactors and inhibitors. Am J Physiol. 1954 Oct;179(1):149–153. doi: 10.1152/ajplegacy.1954.179.1.149. [DOI] [PubMed] [Google Scholar]
  12. JOHNSON S. A., SEEGERS W. H. Use of purified prothrombin in the study of hemophilia and plasma thromboplastin component (PTC) deficiency. J Appl Physiol. 1954 Jan;6(7):429–436. doi: 10.1152/jappl.1954.6.7.429. [DOI] [PubMed] [Google Scholar]
  13. LANGDELL R. D., GRAHAM J. B., BRINKHOUS K. M. Prothrombin utilization during clotting: comparison of results with the two-stage and one-stage methods. Proc Soc Exp Biol Med. 1950 Jun;74(2):424–427. doi: 10.3181/00379727-74-17927. [DOI] [PubMed] [Google Scholar]
  14. LANGDELL R. D., WAGNER R. H., BRINKHOUS K. M. Antihemophilic factor (AHF) levels following transfusions of blood, plasma and plasma fractions. Proc Soc Exp Biol Med. 1955 Feb;88(2):212–215. doi: 10.3181/00379727-88-21540. [DOI] [PubMed] [Google Scholar]
  15. LANGDELL R. D., WAGNER R. H., BRINKHOUS K. M. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med. 1953 Apr;41(4):637–647. [PubMed] [Google Scholar]
  16. MOSHER R. E., BOYLE A. J. The use of flame photometry for the quantitative determination of sodium and potassium in plasma and urine. Am J Clin Pathol. 1949 May;19(5):461–470. doi: 10.1093/ajcp/19.5_ts.461. [DOI] [PubMed] [Google Scholar]
  17. QUICK A. J., HUSSEY C. V. Prothrombin and the one-stage prothrombin time. Br Med J. 1955 Apr 16;1(4919):934–937. doi: 10.1136/bmj.1.4919.934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. SEEGERS W. H., JOHNSON S. A., FELL C., ALKJAERSIG N. Activation of purified prothrombin with platelets combined with various crude biochemical preparations. Am J Physiol. 1954 Jul;178(1):1–9. doi: 10.1152/ajplegacy.1954.178.1.1. [DOI] [PubMed] [Google Scholar]
  19. TOCANTINS L. M., CARROLL R. T., HOLBURN R. H. The clot accelerating effect of dilution on blood and plasma. Relation to the mechanism of coagulation of normal and hemophilic blood. Blood. 1951 Aug;6(8):720–739. [PubMed] [Google Scholar]
  20. TOCANTINS L. M., HOLBURN R. R., CARROLL R. T. Response of plasma to excess of thromboplastin as a measure of prothrombin activity. Proc Soc Exp Biol Med. 1951 Apr;76(4):623–630. doi: 10.3181/00379727-76-18579. [DOI] [PubMed] [Google Scholar]
  21. TOCANTINS L. M. Hemophilic syndromes and hemophilia. Blood. 1954 Mar;9(3):281–285. [PubMed] [Google Scholar]
  22. TOCANTINS L. M. The maintenance of the fluidity and coagulability of blood; physiological and surgical aspects. Surg Clin North Am. 1949 Dec;29:1835–1848. doi: 10.1016/s0039-6109(16)32893-6. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES